These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37160242)

  • 21. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2017.
    Coombs GW; Daley DA; Lee YT; Pang S
    Commun Dis Intell (2018); 2019 Sep; 43():. PubMed ID: 31522665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP).
    Coombs GW; Daley DA; Shoby P; Mowlaboccus S
    Commun Dis Intell (2018); 2022 Dec; 46():. PubMed ID: 36529133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.
    Britt NS; Patel N; Shireman TI; El Atrouni WI; Horvat RT; Steed ME
    J Antimicrob Chemother; 2017 Feb; 72(2):535-542. PubMed ID: 27999028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feedback to clinicians on preventable factors can reduce hospital onset Staphylococcus aureus bacteraemia rates.
    Kok J; O'Sullivan MV; Gilbert GL
    J Hosp Infect; 2011 Oct; 79(2):108-14. PubMed ID: 21741724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections - an observational, retrospective review.
    Bao H; Igwilo-Alaneme R; Sonia F; Cowman K; Kahn M; Nori P
    Ther Adv Infect Dis; 2024; 11():20499361241245523. PubMed ID: 38645297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries.
    Ammerlaan H; Seifert H; Harbarth S; Brun-Buisson C; Torres A; Antonelli M; Kluytmans J; Bonten M;
    Clin Infect Dis; 2009 Oct; 49(7):997-1005. PubMed ID: 19719417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
    J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.
    Falcón R; Mateo E; Oltra R; Giménez E; Albert E; Torres I; Navarro D
    Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):903-912. PubMed ID: 30729396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study.
    Chang HJ; Hsu PC; Yang CC; Siu LK; Kuo AJ; Chia JH; Wu TL; Huang CT; Lee MH
    J Antimicrob Chemother; 2012 Mar; 67(3):736-41. PubMed ID: 22169187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013.
    Coombs GW; Nimmo GR; Daly DA; Le TT; Pearson JC; Tan HL; Robinson JO; Collignon PJ; McLaws ML; Turnidge JD;
    Commun Dis Intell Q Rep; 2014 Dec; 38(4):E309-19. PubMed ID: 25631593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System.
    Gonzalez J; Andrade DC; Niu J
    Clin Infect Dis; 2021 Oct; 73(7):e1436-e1442. PubMed ID: 33211794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. National surveillance of antimicrobial susceptibilities to ceftaroline, dalbavancin, telavancin, tedizolid, eravacycline, omadacycline, and other comparator antibiotics, and genetic characteristics of bacteremic Staphylococcus aureus isolates in adults: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) program in 2020.
    Chen CH; Wu PH; Lu MC; Ho MW; Hsueh PR;
    Int J Antimicrob Agents; 2023 Apr; 61(4):106745. PubMed ID: 36758774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia.
    Arrieta AC; Bradley JS; Popejoy MW; Bensaci M; Grandhi A; Bokesch P; Glasser C; Du L; Patino H; Kartsonis NA
    Pediatr Infect Dis J; 2018 Sep; 37(9):893-900. PubMed ID: 29406465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis.
    Suárez M; Pérez-Landeiro A; Sanjurjo A; Lima O; Sousa A; López A; Martínez-Lamas L; Cabrera X; Rubianes M; Pérez-Rodríguez MT
    Int J Infect Dis; 2024 Jan; 138():41-45. PubMed ID: 37931892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Bigseth RS; Sandholdt H; Petersen A; Østergaard C; Benfield T; Thorlacius-Ussing L
    Microbiol Spectr; 2022 Jun; 10(3):e0153021. PubMed ID: 35438533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2018.
    Coombs GW; Daley DA; Mowlaboccus S; Lee YT; Pang S;
    Commun Dis Intell (2018); 2020 Mar; 44():. PubMed ID: 32178604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains.
    Citron DM; Tyrrell KL; Goldstein EJ
    Diagn Microbiol Infect Dis; 2014 Aug; 79(4):438-40. PubMed ID: 24972854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
    Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.